AI-enabled virtual primary care
InstaDoc
InstaDoc is a patient-facing AI symptom checker and asynchronous telemedicine pathway for possible-condition and next-step guidance, prescriptions, sick notes, and referral letters. It may expand agency through free, patient-initiated symptom reflection and low-cost action support. Confidence remains limited because the homepage's urgent-care and clinician-review framing conflicts with legal terms requiring independent board-certified-physician verification and prohibiting urgent-care use; prices differ across pages; state availability is unpublished; the e-prescribing integration is labeled certification pending; the AI model/provider is not disclosed; and no independent validation was found.
Public-source research has been drafted, often with AI assistance. No comprehensive human review is recorded unless the profile provenance says so.
Summary judgment · 82% toward patient-directed
Potentially agency-expanding, with clinical-governance, verification, and disclosure contradictions
Patients choose InstaDoc, define the problem, can begin without an account, decide whether to pursue paid care, and select a pharmacy. That strongly patient-directed entry could support understanding and action, but public claims about urgent-care scope, clinician review, board-certified-physician verification, prices, state availability, e-prescribing readiness, and the AI data path are not coherent enough for a stronger posture.
Patient agency
How this tool changes agency
The service is designed to organize symptoms, surface possible causes, tests, treatments, and next steps, and connect patients to prescriptions, notes, or referrals. No independent evidence establishes accuracy, safe triage, patient outcomes, or equitable performance.
Use is voluntary, the free assessment can begin without an account, the reviewed flow blocks continuation until legal assent, and patients choose whether to send information for clinical care. Choice is weakened by inconsistent prices, an unpublished state list, unclear e-prescribing readiness, and incomplete disclosure of paid escalation and model data flows.
Patient-facing signals
Who does this AI serve?
Patients choose the tool and problem, enter symptoms, decide whether to pursue paid care, and select a pharmacy. The free assessment also creates a pathway to paid services from Panagea Medical Group, which is legally described as separate from InstaDoc but shares a common founder.
Can patients tell AI is involved?
AI is explicit on the homepage, service cards, terms, and pre-consent assessment flow. The site describes AI-generated questions, summaries, possible conditions, and care suggestions.
Can patients meaningfully choose?
Use is voluntary, the free assessment can begin without an account, the reviewed flow blocks continuation until legal assent, and patients choose whether to send information for clinical care. Choice is weakened by inconsistent prices, an unpublished state list, unclear e-prescribing readiness, and incomplete disclosure of paid escalation and model data flows.
Can patients correct or challenge what the AI produces?
Panagea publishes secure messaging, record export, and an amendment-request workflow for clinical records. No direct correction, model-provenance, human-review, or appeal workflow for the free AI assessment was found, and the terms place independent board-certified-physician verification on the user.
Does it help patients understand or act?
The service is designed to organize symptoms, surface possible causes, tests, treatments, and next steps, and connect patients to prescriptions, notes, or referrals. No independent evidence establishes accuracy, safe triage, patient outcomes, or equitable performance.
Text findings
Why is this tool included?
Brought to HugoScore through a founder-profile screenshot; not an endorsement
A screenshot of founder Jon Pangia's public LinkedIn profile brought InstaDoc to HugoScore's attention on 2026-07-30. The screenshot was treated as a lead, not evidence for product claims. Publishing this draft does not endorse the founder, vendor, medical group, or service.
Who is left out or burdened?
Low-cost access upside, with geography, language, disability, verification, and digital burdens
Free entry and low advertised prices may reduce cost, travel, waiting-room, and specialist-gatekeeping burdens. The service is U.S.-only, 18+, English-first, internet-dependent, and based on typed self-report without a physical exam. State availability, accessibility, multilingual support, low-literacy testing, caregiver/proxy controls, and subgroup performance are not disclosed. The terms' board-certified-physician verification requirement places a large burden on users seeking an access alternative.
What happens to patient data?
Meaningful no-sale/no-training and patient-rights claims, incomplete AI data path
InstaDoc says free intake remains anonymous until a patient chooses to share it with a medical entity and says it does not sell health data, share it with advertisers, or use it to train AI models. Panagea lists Supabase, DoseSpot, Stripe, Twilio, Resend, and IDScan and publishes access, export, amendment, disclosure-accounting, restriction, and revocation rights. The AI model/provider, inference location, logging, anonymous-session retention, quantified clinical retention, de-identification method, and full business-associate path are not disclosed.
Are the clinical boundaries clear?
Important limits are visible, but the public boundary is internally inconsistent
Emergency exclusions, AI fallibility, asynchronous-care risks, controlled-substance limits, and clinician authority are public. The homepage markets common urgent-care services while the terms prohibit urgent-care use; licensed-professional review language conflicts with a board-certified-physician verification condition; and prescription promises coexist with public statements that e-prescribing certification is pending. Current FDA guidance is function-specific; HugoScore makes no regulatory determination.
Who defined what good looks like?
Vendor- and clinician-founder-defined
The citations hub and editorial policy are useful transparency measures, and launch coverage reports founder claims of internal competitor benchmarking. No public validation protocol, test set, model version, failure analysis, triage sensitivity, calibration, subgroup results, patient-partnered evaluation, prospective outcome study, accessibility audit, security audit, peer-reviewed study, or independent replication was found.
Review provenance
Criteria
Same HugoScore CAIHL-derived criteria for every tool; public criteria are displayed from site/data/criteria.json, with fuller method notes in SCORING_FRAMEWORK.md.
Reviewer
AI-assisted public-source draft prepared in OpenAI Codex; no named human reviewer recorded.
AI / model
OpenAI Codex / GPT-5-based assistant.
Human review
No comprehensive human review has been completed or claimed for this draft profile.
Review date
2026-07-30
Limitations
No completed symptom assessment, real patient data, account, identity verification, payment, prescription, note, referral, clinician interaction, source-code inspection, vendor interview, security/accessibility audit, legal review, regulatory determination, or independent clinical validation.
Review method
Deep public-source review of the live InstaDoc homepage, pre-consent symptom-checker flow, pricing, privacy, terms, editorial, citations, medical-team, and state-availability pages; Panagea Medical Group's About, privacy, patient-consent, and workflow pages; current FDA and HHS guidance; credible launch coverage; and searches for independent evaluation. No completed assessment, real patient data, account, identity verification, payment, prescription, note, referral, clinician interaction, source-code review, security/accessibility audit, legal review, regulatory determination, or independent clinical validation.
Draft profile · Low-to-medium draft, official live-product and policy review plus limited launch reporting; no independent validation